Mizuho analyst Anthony Petrone raised the firm’s price target on Cooper Companies to $385 from $375 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics models ahead of the Q4 earnings season to reflect feedback from last week’s West Coast broker conference and ongoing hospital/physician channel checks. The general tone suggested the elevated respiratory viral volumes did not impact inpatient volumes, although some pockets of weakness did emerge in outpatient elective procedures, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on COO:
- Cooper Companies price target raised to $375 from $350 at Piper Sandler
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Cooper Companies initiated with a Buy at Mizuho
- CooperCompanies Sets Annual Meeting and Stockholder Record Dates
- Piper Sandler medical tech analysts hold analyst/industry conference call